CAMBRIDGE, Mass., Feb. 22 /PRNewswire-FirstCall/--
Biogen, Inc. (Nasdaq: BGEN) will be giving a company update at the Lehman
Brothers' Global Health Care Conference on February 26, 2002 at 8:30 am
(eastern).
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
To access the live audio of the presentation please dial:
800-553-2720 (Domestic)
303-713-7920 (International)
ID#: 1561213
To access the audio replay of the presentation please dial:
800-625-5288 (Domestic)
303-804-1855 (International)
ID#: 1561213
Forward Looking Statements
In addition to historical information, this presentation contains forward-
looking statements within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. These statements are based
on the Company's current beliefs and expectations as to such future results
and performance. Risks and uncertainties which could cause actual results and
performance to differ materially from the Company's current expectations are
described in the Company's periodic reports filed with the Securities and
Exchange Commission.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.
Contact:
Rob Jacobson
Investor Relations Specialist
Biogen, Inc.
Rob_Jacobson@Biogen.com
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Rob Jacobson, Investor Relations Specialist
of Biogen, Inc., Rob_Jacobson@Biogen.com
|
